Neurothera Labs Inc. Closes Final Tranche of Non-Brokered Private Placement
NeuroThera Labs Inc. Closes First Tranche Of Non-Brokered Private Placement
NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination
NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
What's Going On With SciSparc Shares On Friday?
NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
NeuroThera Labs Announces Upsize to Private Placement
NeuroThera Labs Announces C$5,000,000 Private Placement of Units
Neurothera Labs Inc. Announces Closing Of Acquisition Of Majority Stake In Cliniquantum Ltd.
Neurothera Labs Inc. Provides Update On Proposed Acquisition Of Majority Stake In Cliniquantum Ltd.
Neurothera Labs Announces Adoption of Semi-Annual Reporting
Neurothera Labs Announces Continuance into Ontario
Neurothera Labs Engages bullVestor for Investor Relations Activities
NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
Neurothera Labs Inc. Announces Definitive Agreement To Acquire Majority Stake In Cliniquantum Ltd.
Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA
Neurothera Labs Announces Results of AGM
Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects
Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company
Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression